A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT06100744 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Juvenile Psoriatic Arthritis

Interventions

DRUG: Adalimumab
DRUG: Risankizumab

Sponsor

AbbVie